SEC Form 4 · accession 0001493152-17-002852
PetLife Pharmaceuticals, Inc. · PTLF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ralph T Salvagno
Officer — CEO · Director · 10% Owner
Period of report
Dec 29, 2015
Accepted (ET)
Mar 27, 2017 · 6:15 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001354591
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 29, 2015 | P | 100,000 | $0.25 | A | 100,000 | I | By Grand Street Ventures, LLC |
| Common StockF1 | Feb 12, 2016 | P | 250,000 | $0.64 | A | 350,000 | I | By Grand Street Ventures, LLC |
| Common StockF1 | Feb 12, 2016 | P | 540,000 | $0.46 | A | 890,000 | I | By Grand Street Ventures, LLC |
| Common StockF1 | Feb 12, 2016 | P | 250,000 | $0.64 | A | 1,140,000 | I | By Grand Street Ventures, LLC |
| Common StockF2 | Feb 23, 2017 | A | 11,160,000 | $0.50 | A | 12,300,000 | I | By Grand Street Ventures, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $0.25 | Jun 9, 2016 | A | 2,000,000 | A | Jun 9, 2016 | Jun 9, 2019 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1Adjusted for the issuer's 1-for-5 reverse stock split effected in September 2016.
- F2For services valued at $0.50/share.
- F3The issuer granted Dr. Salvagno options to purchase 2,000,000 shares of common stock at an exercise price of 50% of the market price or $0.25/share, whichever is higher.